Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Esflurbiprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 1.00 |
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 11/20 | 1.00 |
| ▸ | AKR1C2 | P52895 | 11/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | FABP2 | P12104 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | AKR1C4 | P17516 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tarenflurbil SCHEMBL26131 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL1070292 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Tarenflurbil SCHEMBL29350102 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL8754830 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL8754978 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL10029029 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL2248 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL8755275 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL3519037 | 0.98 | AKR1C3 (0.97) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL9877586 | 0.98 | AKR1C3 (0.97) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 441 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486301-B2 | 8-fluoro-4-alkylumbelliferyl α-D-glucopyranoside, biological sterilization indicator including the same and its use in a method of determining efficacy of a sterilization process | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-12-02 | — | — | US | claimed |
| EP-4637708-A2 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | Novaliq GmbH (DE) | 2025-10-29 | — | — | EP | claimed |
| CN-120040283-A | Flurbiprofen axetil salt and preparation method and application thereof | 广东莱恩医药研究院有限公司 | 2025-05-27 | — | — | CN | claimed |
| US-20250146990-A1 | SELF-CONTAINED BIOLOGICAL INDICATOR | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-05-08 | — | — | US | claimed |
| CN-119775137-A | Preparation method of (S) -2- (2-fluoro- [1,1' -biphenyl ] -4-yl) propionic acid | 江苏中卫康医药研发有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-119735507-A | Racemization method for inhibiting preparation process of ifenprodil by using buffer salt | 南京海纳医药科技股份有限公司 | 2025-04-01 | — | — | CN | claimed |
| WO-2024133913-A9 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | NOVALIQ GMBH (DE) | 2025-03-20 | — | — | WO | claimed |
| WO-2025051134-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | 北京泰德制药股份有限公司 | 2025-03-13 | — | — | WO | claimed |
| US-12228555-B2 | Self-contained biological indicator | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-02-18 | — | — | US | claimed |
| US-12123048-B2 | Fluorinated 4′-alkylumbelliferyl a-D-glucopyranosides, biological sterilization indicators including the same and methods of using the same | Solventum Intellectual Property Company (US) | 2024-10-22 | — | — | US | claimed |
| WO-1997014669-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE CARBOXYLIC ACIDS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1997-04-24 | — | — | WO | claimed |
| EP-0713697-A1 | Analgesic anti-inflammatory adhesive preparations | Tokuhon Corporation (JP) | 1996-05-29 | — | — | EP | claimed |
| US-4489080-A | SYNERGISTIC COMBINATION OF NARCOTIC AND FLURBIPROFEN OR ESTER | THE UPJOHN COMPANY (US) | 1984-12-18 | — | — | US | claimed |
| US-4477468-A | Treatment of type II herpes virus with flurbiprofen | THE UPJOHN COMPANY (US) | 1984-10-16 | — | — | US | claimed |
| US-4473584-A | Treatment of Type I Herpes virus with flurbiprofen | THE UPJOHN COMPANY (US) | 1984-09-25 | — | — | US | claimed |
| US-4443476-A | Treatment of adult respiratory distress syndrome | THE UPJOHN COMPANY (US) | 1984-04-17 | — | — | US | claimed |
| US-4439451-A | Treatment of the blood-brain barrier with flurbiprofen | THE UPJOHN COMPANY (US) | 1984-03-27 | — | — | US | claimed |
| EP-0070714-A1 | Use of ibuprofen or flurbiprofen for the manufacture of a medicament for treating respiratory disorders | THE UPJOHN COMPANY (US) | 1983-01-26 | — | — | EP | claimed |
| US-4014993-A | Inhibition of platelet aggregation with substituted phenylhydratropic acid compounds | THE UPJOHN COMPANY (US) | 1977-03-29 | — | — | US | claimed |
| US-3973037-A | Hydratropic acid derivatives in the treatment of non-inflammatory allergic reactions | THE UPJOHN COMPANY (US) | 1976-08-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12123048-B2 | Fluorinated 4′-alkylumbelliferyl a-D-glucopyranosides, biological sterilization indicators including the same and methods of using the same | ALPG, UNG, GUSB | PTGS1 2638/4885PTGS2 3036/4885AKR1C3 103/4885 |
| US-12486301-B2 | 8-fluoro-4-alkylumbelliferyl α-D-glucopyranoside, biological sterilization indicator including the same and its use in a method of determining efficacy of a sterilization process | ALPG, UNG, UGDH | PTGS1 2242/4885PTGS2 2554/4885AKR1C3 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.